The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 22 January 2008, www.theannals.com, DOI 10.1345/aph.1K086.
The Annals of Pharmacotherapy: Vol. 42, No. 2, pp. 226-236. DOI 10.1345/aph.1K086
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Google Scholar
Right arrow Articles by Kent, M. E
Right arrow Articles by Romanelli, F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kent, M. E
Right arrow Articles by Romanelli, F.

STDS AND HIV/AIDS

Reexamining Syphilis: An Update on Epidemiology, Clinical Manifestations, and Management

Molly E Kent, PharmD

Infectious Diseases Clinical Specialist, Department of Pharmacy, University of Maryland Medical Center, Baltimore, MD

Frank Romanelli, PharmD MPH BCPS

Associate Professor, Pharmacy Practice and Science; Assistant Dean for Education, College of Pharmacy, University of Kentucky, Lexington, KY

Reprints: Dr. Romanelli, College of Pharmacy, University of Kentucky, 725 Rose St., Lexington, KY 40536, fax 859/323-0069, froma2{at}email.uky.edu

OBJECTIVE: To review the epidemiology, clinical features, diagnosis, and treatment of syphilis.

DATA SOURCES: Studies and reviews were abstracted from MEDLINE (1950-April 2007) using the search term syphilis. All papers were cross-referenced to identify additional studies and reviews for inclusion.

STUDY SELECTION AND DATA EXTRACTION: Pertinent original research articles, review articles, and book chapters were evaluated.

DATA SYNTHESIS: Syphilis is a spirochetal disease that has plagued mankind for centuries. Following a low incidence of syphilis in the US for the last 2 decades, rates are now increasing both in the US and other parts of the world. Once acquired, syphilis can pass through 4 distinct stages of disease: primary syphilis, secondary syphilis, latent syphilis, and tertiary syphilis, with each stage being characterized by different symptoms and levels of infectivity. Diagnosis is made primarily by serologic assays with nontreponemal tests such as the Venereal Disease Research Laboratory and the Rapid Plasma Reagin assay used for screening. Treponemal tests including the Treponema pallidum particle agglutination and the fluorescent treponemal antibody absorption test are then used for confirmation. Recommended treatment regimens are based largely on uncontrolled trials and clinical experience. Penicillin is the treatment of choice, with the preparation and treatment duration varying for different stages. Benzathine penicillin is the treatment of choice for all stages of syphilis except neurosyphilis, for which aqueous crystalline penicillin or procaine penicillin is used due to the central nervous system penetration of these formulations. Coinfection with both syphilis and HIV occurs frequently due to common risk factors. These 2 diseases interact with each other, making both diagnosis and treatment more complicated.

CONCLUSIONS: Clinicians should be aware of the signs and symptoms of syphilis as well as current guidelines for the management and treatment of this disease.

Key Words: acquired immunodeficiency syndrome, human immunodeficiency virus, syphilis

Published Online, January 22, 2008. www.theannals.com, DOI 10.1345/aph.1K086

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER:
407-000-08-002-H01





homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.